Huons Global Co. Ltd Market Cap ($146.23 Million)
Market Cap & Net Worth: Huons Global Co. Ltd (084110)
Huons Global Co. Ltd market cap. Huons Global Co. Ltd (KQ:084110) has a market capitalization of $146.23 Million (₩215.78 Billion) as of November 4, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #17543 globally and #720 in its home market, demonstrating a -3.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Huons Global Co. Ltd's stock price ₩19890.00 by its total outstanding shares 10848500 (10.85 Million). Also see Huons Global Co. Ltd (084110) cash conversion ratio for how efficiently the company converts equity into cash flow.
Huons Global Co. Ltd Market Cap History (2015–2026)
Huons Global Co. Ltd market cap history from 2015 to 2026. Data shows change from $366.42 Million to $146.23 Million (-7.61% CAGR). Check 084110 stock price and chart for real-time trading data and today's change.
Index Memberships
Huons Global Co. Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$203.83 Billion | 0.07% | #263 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$203.83 Billion | 0.07% | #263 of 1384 |
Weight: Huons Global Co. Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Huons Global Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Huons Global Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 084110 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.00x
Huons Global Co. Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.01x
Huons Global Co. Ltd's market cap is 0.01 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $175.58 Million | $163.71 Billion | $514.64 Billion | 0.00x | 0.00x |
| 2017 | $301.49 Million | $323.96 Billion | $25.65 Billion | 0.00x | 0.01x |
| 2018 | $254.12 Million | $378.69 Billion | $29.45 Billion | 0.00x | 0.01x |
| 2019 | $214.91 Million | $449.42 Billion | $26.66 Billion | 0.00x | 0.01x |
| 2020 | $190.37 Million | $523.05 Billion | $42.70 Billion | 0.00x | 0.00x |
| 2021 | $266.40 Million | $574.65 Billion | $3.99 Billion | 0.00x | 0.07x |
| 2022 | $133.08 Million | $664.36 Billion | -$60.25 Billion | 0.00x | N/A |
| 2023 | $169.86 Million | $758.38 Billion | $38.38 Billion | 0.00x | 0.00x |
| 2024 | $317.97 Million | $813.46 Billion | $25.79 Billion | 0.00x | 0.01x |
| 2025 | $376.42 Million | $847.45 Billion | $28.84 Billion | 0.00x | 0.01x |
Competitor Companies of 084110 by Market Capitalization
Companies near Huons Global Co. Ltd in the global market cap rankings as of November 4, 2026. Also see balance sheet size of Huons Global Co. Ltd for a full breakdown of the balance sheet.
Key companies related to Huons Global Co. Ltd by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5272 globally with a market cap of $2.49 Billion USD ( ₩3.67 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8989 globally with a market cap of $902.70 Million USD ( ₩1.33 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9557 globally with a market cap of $793.12 Million USD ( ₩1.17 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10371 globally with a market cap of $674.16 Million USD ( ₩994.80 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5272 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.49 Billion | ₩171400.00 |
| #8989 | ST Pharm Co.Ltd | KQ:237690 | $902.70 Million | ₩71400.00 |
| #9557 | NatureCell Co.Ltd | KQ:007390 | $793.12 Million | ₩22050.00 |
| #10371 | Oscotec Inc | KQ:039200 | $674.16 Million | ₩35400.00 |
Market Capitalization of Huons Global Co. Ltd (2015–2026)
Market capitalization of Huons Global Co. Ltd from 2015 to today. Between 2015 and today, Huons Global Co. Ltd's market cap moved from $366.42 Million to $ 146.23 Million, with a yearly change of -7.61%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩146.23 Million | -61.15% |
| 2025 | ₩376.42 Million | +18.38% |
| 2024 | ₩317.97 Million | +87.19% |
| 2023 | ₩169.86 Million | +27.64% |
| 2022 | ₩133.08 Million | -50.05% |
| 2021 | ₩266.40 Million | +39.94% |
| 2020 | ₩190.37 Million | -11.42% |
| 2019 | ₩214.91 Million | -15.43% |
| 2018 | ₩254.12 Million | -15.71% |
| 2017 | ₩301.49 Million | +71.71% |
| 2016 | ₩175.58 Million | -52.08% |
| 2015 | ₩366.42 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Huons Global Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $146.23 Million USD |
| MoneyControl | $146.23 Million USD |
| MarketWatch | $146.23 Million USD |
| marketcap.company | $146.23 Million USD |
| Reuters | $146.23 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Huons Global Co. Ltd
Huons Global Co., Ltd. provides medical solutions for human health in South Korea and internationally. The company offers oral solid form products in the areas of circulatory system, metabolic, anti-pyretic analgesic anti-inflammatory, musculoskeletal system, digestive system, antihistamine, respiratory system, antibiotic, well-being, urogenital system, other chemotherapeutic, and others; and inj… Read more